Dr. Yicheng Mao received her Ph.D. degree in pharmaceutical sciences from the Ohio State University, U.S.A. in 2012. Since 2013, she has been working as an assistant professor at School of Pharmacy, Fudan University in Department of Pharmacology and Biochemistry. Dr. Mao is presently engaged in multidisciplinary studies on antibody- and nanoparticle-based targeting therapies for chronic lymphocytic leukemia. She is also interested in fields of formulation design for gas transmitter small molecule drugs and mechanism study.
Pharmaceutical pharmacology; Hydrogen sulfide; Leukemia
Education
2012 Ph.D. School of Pharmacy, The Ohio State University, USA
2006 B.S. in Biotechnology, East China University of Science and Technology
Professional Experiences
Associate Professor (Dec 2017-Present)
Assistant Professor (Apr 2013-Dec 2017)
Department of Pharmacology, School of Pharmacy, Fudan University
Teaching Activities
Undergraduate courses:
Pharmacology
Professional Pharmacy English
Case-based Pharmacology (Course taught in English)
General Pharmacology
Pharmacological Comprehensive Experiments
Grants & Projects
1. Preclinical study of a novel double-gas signaling molecule donor compound ZYZ-803 on angiogenesis (Shanghai Committee of Science and Technology, 2016-2019)
2. Mechanism study of non-drug-loaded nano-immunoliposomes in lymphoma treatment (NSFC, 2015-2017)
3. Protective effects and molecular mechanism of new SPRC liposomal formulation in rat heart failure (Shanghai Chenguang Talent Program, 2015-2017)
Awards & Honors
2015 Shanghai Chenguang Talent Program
2013 Shanghai Pujiang Talent Program
Memberships
Shanghai Pharmacology Society, member
Chinese Pharmacology Society, member
Selected Publications（latest 5 yrs，<20 papers）
1. Dan Wu, Qingxun Hu, Ying Xiong, Deqiu Zhu, Yicheng Mao*, Yi Zhun Zhu*, Novel H2S-NO hybrid molecule (ZYZ-803) promoted synergistic effects against heart failure, Redox Biology(SCI), IF:6.325; 2018, 15: 243-252;
2. Rajeswaran Mani#, Yicheng Mao#, Frank W. Frissora, Chi-Ling Chiang, Jiang Wang, Yuan Zhao, Yun Wu, Bo Yu, Ribai Yan, Xiaokui Mo, Lianbo Yu, Joseph Flynn, Jeffrey Jones, Leslie Andritsos, Sivasubramanian Baskar, Christoph Rader, Mitch A Phelps, Ching-Shih Chen, Robert J. Lee, John C. Byrd, L. James Lee, and Natarajan Muthusamy, Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia[J] Leukemia(SCI), IF:12.104; 2015, 29(2): 346-55;
3. Yicheng Mao, Jiang Wang, Yuan Zhao, Yun Wu, Kwang Joo Kwak, Ching-Shih Chen, John C. Byrd, Robert J. Lee, Mitch A. Phelps, L. James Lee and Natarajan Muthusamy, A novel liposomal formulation of FTY720 (Fingolimod) for promising enhanced targeted delivery[J] Nanomedicine: Nanotechnology, Biology, and Medicine(EI), IF:6.155; 2014, 10 (2): 393-400;
4. Yicheng Mao#, Jiang Wang#, Yuan Zhao, Ribai Yan, Hao Li, Ching-Shih Chen, Robert J. Lee, John C. Byrd, L. James Lee, Natarajan Muthusamy and Mitch A. Phelps, Quantification of OSU-2S, a novel derivative of FTY720, in mouse plasma by liquid chromatography-tandem mass spectrometry[J] J Pharm Biomed Anal(SCI), IF:2.979; 2014, 98:160-5;
5. Bo Yu#, Yicheng Mao#, Yuan Yuan, Chaofang Yue, Xinmei Wang, Xiaokui Mo, David Jarjoura, Michael E. Paulaitis, Robert J. Lee, John C. Byrd, L. James Lee and Natarajan Muthusamy, Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells[J] Biomaterials(SCI), IF:8.312; 2013, 34 (26): 6185-6193;
